BSGM - BioSig Technologies, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
6.57
-0.08 (-1.20%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close6.65
Open6.63
Bid6.57 x 1800
Ask6.64 x 900
Day's Range6.34 - 6.66
52 Week Range3.86 - 9.97
Volume70,235
Avg. Volume67,915
Market Cap146M
Beta (5Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)-1.30
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.50
  • GlobeNewswire

    BioSig Technologies Announces New Collaboration on Development of Artificial Intelligence Solutions in Healthcare

    Westport, CT, Dec. 03, 2019 -- ·The Company partners with Reified Capital, a provider of advanced artificial intelligence-focused technical advisory services to the private.

  • BioSig Technologies Partners Mayo Clinic to Treat Arrhythmia
    Zacks

    BioSig Technologies Partners Mayo Clinic to Treat Arrhythmia

    BioSig Technologies (BSGM) signs agreement with Mayo Foundation for improving arrhythmia treatment along with covering therapies for autonomic nervous system disease.

  • GlobeNewswire

    BioSig Technologies Signs Three New Licensing Agreements with Mayo Clinic

    Under the terms of the newly reached agreements the Company plans to establish a new product pipeline to complement more advanced features of BioSig’s first product, PURE EPTM System, and develop solutions for novel ways to treat autonomic nervous system disease. The new R&D pipeline includes hardware, software and algorithmic solutions to be integrated into PURE EPTM platform technology.

  • GlobeNewswire

    BioSig Commences Clinical Trial Enrollment for PURE EP System

    Texas Cardiac Arrhythmia Research Foundation (TCARF) in Austin, Texas, is the first institution to conduct patient cases under the clinical trial titled, “Novel Cardiac Signal Processing System for Electrophysiology Procedures (PURE EP 2.0 Study)”. Eight patient enrollments were achieved during the first week of the trial.

  • GlobeNewswire

    BioSig Technologies Welcomes the Creation of New Bioelectronic Medicine Alliance

    The alliance grew out of an invitation-only roundtable and working group that BioSig organized earlier this year, at which a distinguished group of researchers, entrepreneurs, and healthcare experts agreed on the need for a collaborative effort to create a shared vision for bioelectronic medicine.

  • GlobeNewswire

    BioSig Technologies Issues November 2019 Shareholder Letter

    Westport, CT, Nov. 14, 2019 -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal.

  • GlobeNewswire

    BioSig Technologies Invests in Union College’s Internship Program

    BioSig Technologies, Inc. (BSGM) (“BioSig” or “The Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company’s founder, Chairman & CEO Kenneth L. Londoner is making a gift to New York-based Union College in order to support the school’s growing internship program. Last summer, a handful of Union students joined BioSig’s internship program, a highly immersive internship experience, which gives students an opportunity to enhance their professional interests in an entrepreneurial environment.

  • GlobeNewswire

    Sasha Gentling, CFA Joins BioSig as Director of Business Development

    BioSig Technologies, Inc. (BSGM) (“BioSig” or “The Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company further expanded its Investor Relations team by appoining Ms. Sasha Gentling, CFA as Director of Business Development and Investments. Minnesota based Ms. Gentling becomes the first employee of BioSig’s Rochester office.

  • GlobeNewswire

    BioSig Appoints Andrew Ballou as Vice President of Investor Relations

    BioSig Technologies, Inc. (BSGM) (“BioSig” or “The Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company appointed Mr. Andrew (“Andy”) Gornell Ballou as Vice President of Investor Relations. Mr. Ballou brings to BioSig over 25 years of experience in capital markets, including institutional equity sales and research analysis.

  • Here's Why We're Watching BioSig Technologies's (NASDAQ:BSGM) Cash Burn Situation
    Simply Wall St.

    Here's Why We're Watching BioSig Technologies's (NASDAQ:BSGM) Cash Burn Situation

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • GlobeNewswire

    BioSig Opens a Technology Development Office in Rochester, MN

    BioSig Technologies, Inc. (BSGM) (“BioSig” or “The Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company is opening a new technology development office at Discovery Square, a 16 block sub-district built in collaboration with Mayo Clinic in Rochester, Minnesota. Discovery Square life science hub forms a part of Destination Medical Center (DMC), a unique 20-year economic development initiative in Rochester, MN.

  • GlobeNewswire

    BioSig to Participate at The 14th Annual International Symposium on Ventricular Arrhythmias: Pathophysiology & Therapy

    BioSig Technologies, Inc. (BSGM), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company will be exhibiting at the 14th Annual International Symposium on Ventricular Arrhythmias: Pathophysiology & Therapy on October 11-12, 2019 at Hyatt at the Bellevue in Philadelphia, PA. The symposium is co-hosted by the Department of Medicine, Division of Cardiology, University of Pennsylvania Health System, Philadelphia, PA and the Division of Cardiology, The Mount Sinai Hospital, New York, NY. This course has been developed to meet the educational needs of electrophysiologists, cardiologists and other physicians and associated professionals with an interest in the pathophysiology and management of ventricular arrhythmias.

  • GlobeNewswire

    BioSig to Present Clinical Observations at Venice Arrhythmias 2019

    BioSig Technologies, Inc. (BSGM), a medical technology company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced the PURE EPTM System will be highlighted in a poster presentation at the Venice Arrhythmias conference being held on October 3-5, 2019 in Venice, Italy.

  • GlobeNewswire

    Global Marketing and Strategy Leader Martha Pease Joins BioSig Board of Directors

    Ms. Pease brings to the Company over 30 years of recognition and experience leading organizations in customer centric growth strategy and creating digital leverage powered by data analytics to increase shareholder value.

  • BioSig Technologies-Mayo Clinic Ink Electrophysiology Deal
    Zacks

    BioSig Technologies-Mayo Clinic Ink Electrophysiology Deal

    This collaboration is expected to bolster BioSig's (BSGM) commitment toward offering higher quality patient care by introducing innovative technological solutions to medicine.

  • GlobeNewswire

    BioSig Technologies Signs a New Licensing Agreement with Mayo Clinic

    The new agreement aims to develop a new product pipeline to support some of the more advanced features of BioSig’s first product, PURE EP™ System. The development program will be run under the leadership of Samuel J. Asirvatham, M.D., Mayo Clinic’s Vice-Chair of Innovation and Medical Director, Electrophysiology Laboratory.

  • BioSig Technologies, Inc. (NASDAQ:BSGM) Insiders Increased Their Holdings
    Simply Wall St.

    BioSig Technologies, Inc. (NASDAQ:BSGM) Insiders Increased Their Holdings

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

  • GlobeNewswire

    BioSig‘s Subsidiary NeuroClear Technologies, Inc. Raises $3.7 million

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that its subsidiary, NeuroClear Technologies, Inc., raised $3.7 million in an initial seed round. Founded in November 2018, NeuroClear Technologies, Inc. aims to address some of the biggest challenges in bioelectronic medicine, including, but not limited to, targeted nerve stimulation and a closed feedback loop system to provide appropriate stimulation. NeuroClear intends to build up on the core competencies in recording and analysis of intracardiac, surface ECG and neuronal signals, which have been already validated by BioSig, and develop a dedicated product line to address and/or advance current therapies within a number of markets, such as cognitive disorders and nephrology.

  • GlobeNewswire

    BioSig Allowed Additional Foundational US Patent for its PURE EP(tm) System

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the US Patent Office has allowed another foundational patent including additional 29 patent claims covering its PURE EPTM System. The patent application number 16/271,466 entitled "Systems and Methods for Signal Acquisition and Visualization," was filed on May 9, 2018 and subject to an accelerated Track One patent application filed on February 8, 2019.  The patent has not yet been published.

  • GlobeNewswire

    Julie Stephenson Joins BioSig as Senior Director of Clinical Affairs

    Westport, CT, July 24, 2019 -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing technology platform.

  • GlobeNewswire

    Olivier Chaudoir Joins BioSig as Director of Marketing

    Westport, CT, July 18, 2019 -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing technology platform.

  • GlobeNewswire

    BioSig Technologies, Inc. to Receive 15 Units of PURE EP™ System from Manufacturer for Commercial Installation - Corrected Version

    BioSig Technologies, Inc. (NASDAQ:BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that it will be receiving 15 units of its PURE EP™ System from its manufacturer in preparation for the Company’s limited market release later this month.

  • GlobeNewswire

    BioSig Technologies, Inc. to Receive 15 Units of PURE EP™ System from Manufacturer for Commercial Installation

    BioSig Technologies, Inc. (NASDAQ:BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that it will be receiving 15 units of its PURE EP™ System from its manufacturer in preparation for the Company’s limited market release later this month.

  • GlobeNewswire

    Manasi Patwardhan Joins BioSig as Director of Strategic Planning

    Westport, CT, July 11, 2019 -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing technology platform.

  • BioSig Technologies (NASDAQ:BSGM) Shareholders Have Enjoyed An Impressive 148% Share Price Gain
    Simply Wall St.

    BioSig Technologies (NASDAQ:BSGM) Shareholders Have Enjoyed An Impressive 148% Share Price Gain

    It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...